Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase-1 Study Evaluating the Safety, Pharmacology and Preliminary Activity of MM-310 in Patients With Solid Tumors

Next Previous
Trial Profile

A Phase-1 Study Evaluating the Safety, Pharmacology and Preliminary Activity of MM-310 in Patients With Solid Tumors

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MM 310 (Primary)
  • Indications Adenocarcinoma; Carcinoma; Endometrial cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Small cell lung cancer; Soft tissue sarcoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
  • Focus Adverse reactions; First in man
  • Sponsors Merrimack Pharmaceuticals

    • Most Recent Events

    • 04 Apr 2019 According to a Merrimack Pharmaceuticals media release, the company expects to initiate a workforce reduction as it closes out clinical activities, reflective of its narrowed preclinical pipeline and in line with prior cost-cutting measures.It also expects to provide an update on these efforts with its first quarter 2019 financial results.
    • 04 Apr 2019 According to a Merrimack Pharmaceuticals media release, this study has been terminated as a result of a comprehensive review of available safety data from this phase 1 study. Based on emerging data since the recent amendment of the clinical protocol, the Company has concluded that the study would not be able to reach an optimal therapeutic index for MM-310.
    • 04 Apr 2019 Status changed from recruiting to discontinued as the safety update of this phase I study shows that the study unable to reach optimal therapeutic index for MM-310 due to continued observation of cumulative peripheral neuropathy, according to a Merrimack Pharmaceuticals media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top